AZ 2020 Results: The anti-tumor business is growing rapidly with Enhertu's first year of sales of $200 million

On February 11, 2021, just in time for the traditional Chinese New Year, AstraZeneca announced its 2020 results with full-year revenue of $26.6 billion, with tumors, cardiovascular and respiratory services among AstraZeneca's top three businesses, with the oncology business growing into the most important area and the company's only fast-growing business.
's oncology business revenue was $11.46 billion, up 24% YoY, contributing 43% of the company's results, Oshitini's revenue was $4.3 billion, up 36%, and its cardiovascular business revenue was $5.4 billion, of which Dagley's net income was $1,959 million, up 27% YoY.
Overall, AstraZeneone's 2020 results are the most noteworthy: 1. The oncology business is already the company's heaviest area, the first is to talk about the 3rd generation EGFR representative Ocitini, the drug was approved first to expand the first line of advanced EGFR mutation non-small cell lung cancer, while with ADAURA excellent clinical benefits, approved stage II-IIIA, EGFR mutation non-small cell lung cancer postoperative ancillary treatment; Growth is worth continuing to look forward to; 2. Degree Valium monoanti is another heavyweight in the oncology business, platinum drug release chemotherapy disease stabilization phase III NSCLC patient consolidation treatment, while expanding to a wide range of small cell lung cancer first-line treatment, degree valiant Yudao has achieved rapid growth for 4 consecutive years, however, Dvaliyu monoantigen has made progress in the first line of non-small cell lung cancer, the first line of bladder cancer, the first line of head and neck squamous cell carcinoma, and has not made any breakthrough in the early stage of cancer new auxiliary/assisted treatment, 2021 results are expected to be low double-digit growth; 3. Olapali and Acatini are also fast-growing varieties in the oncology business, and the future of both varieties is still noteworthy: the progress of the Olapali, Paboliju monoantigenic joint programme, of which the first-line maintenance treatment of advanced non-small cell lung cancer is of particular concern; Acatinib has been approved for first-line treatment of chronic lymphatic leukemia, while Acatini vs. Ibtini shows non-inferiority in chronic lymphatic leukemia; Net is another species of concern, in addition to diabetes, Dagley Net in DAPA-HF and DAPA-CKD strong data to support its expansion into heart failure and chronic kidney disease, will continue to grow rapidly in the future; AstraZeneca has developed new coronary prevention and treatment options, such as the new coronavirus vaccine ChAdOx1 nCoV-19, and treatment options such as cocktail therapy tixagevimab/cilgavimab and acatini.
one. 3rd generation EGFR inhibitors: Teresa has grown into an EGFR mutation non-small cell lung cancer full-base early lung cancer (I/II/III phase) breakthrough on the long-term growth of Ocitini, 2021 market sales will continue to maintain high double-digit growth, early 2020 lung cancer postoperative auxiliary treatment program approved is a major breakthrough in the treatment of non-small cell lung cancer.
2020 ASCO conference, Occidini ADAURA (NCT02511106) data showed that Occidini vs. placebo significantly extended disease-free survival in patients with stage II/IIIa non-small cell lung cancer, with 2-year DFS 90% vs. 34%, HR 0.17.
, Ocidini has become a new standard treatment for EGFR mutation non-small cell lung cancer! ADAURA test scheme: II. Key adaptive development is still not smooth, 2021 growth is expected to slow Infineon who is the world's second approved listed PD-L1 single resistance, compared to Roche, AstraZenecon Infinity key adaptive development is not smooth, the current heavy-duty adaptive only Phase III NSCLC consolidation treatment and extensive phase of small cell lung cancer first-line treatment.
Astrain's latest annual report shows that there are several clinical trial projects of Dvaliu monoantigen that are very noteworthy: 1. In the area of lung cancer adaptation, Stage IV non-small cell lung cancer first-line treatment, clinical trial POSEIDON success, whether the future can support the approval of valiyu monoantigen, still need to continue to pay attention to; Esophageal cancer, KUNLUN; Gastric cancer/gastroesophageal junction cancer, MATTERHORN; 3. New auxiliary or complementary treatment options for early cancer, new complementary therapy for non-small cell lung cancer AEGEAN, ADJUVANT.
please refer to the enclosend at the end of the article for details.
wednesday. Acatini: Chronic lymphatic leukemia is not inferior to Ibdinie Worldwide has 4 BTK inhibitors approved for listing in different countries, of which first-in-class variety Ibtinib was approved for listing on November 13, 2013, rapid release, global sales in 2020 reached $6.616 billion, up 16.3% YoY; Approved for listing in the U.S. four years later, sales will grow to $520 million in 2020, still far from Ibdini, and while NCT02477696 clinical data show that Acatini vs. Ibdinib can benefit from chronic lymphatic leukemia and show non-poor effectiveness and safety, it still faces strong competition from Ibdinib.
Thursday. Enhertu will be the new standard for breast cancer, with $200 million in first-year sales of AstraZenecom's oncology business continuing to grow, and the most notable developments in 2021 will be in Duvalliyu, Olapali and Trastuzumab deruxtecan, where progress in the table below requires special attention.
: AstraZeneta Pharmaceuticals' 2020 results (millions of U.S. dollars) are between the most notable clinical projects in the company